Jim Chanos has a way to profit on the drug overpricing backlash and still hates Tesla

The S&P is trying to prune its losses for the week, but some analysts warn that going long too soon could prove costly. For those not going long, Jim Chanos is offering up short ideas — among pharma stocks, in particular.